Previous   Next
HomeBusinessDGCI Approves For Phase 3 Trial of Bharat Biotech Intranasal Vaccine As...

DGCI Approves For Phase 3 Trial of Bharat Biotech Intranasal Vaccine As Booster

Drug Controller General of India (DGCI) on Wednesday granted “in principle” approval to Bharat Biotech to conduct “Phase III superiority study and Phase III booster dose study” trials for its intranasal Covid vaccine. The approval was sought by the vaccine manufacturer last week.

Subject Experts Committee (SEC) has asked the company to submit the protocol for booster study.

On Tuesday, the Committee held a meeting to discuss the vaccine manufacturer Bharat Biotech’s application for clinical trials of its intranasal Covid vaccine as a booster.

The Hyderabad-based manufacturer had proposed the booster dose for those who have been already been inoculated with Covishield and Covaxin vaccines.

According to a source, Bharat Biotech aims to conduct clinical trials on 5,000 healthy subjects: half or 2,500 individuals who have received Covishield and another 2,500 who have been administered Covaxin.

There will be a gap of around six months between the second and the intranasal booster dose. The source said that the nasal booster vaccine is likely to be launched in India by March following clinical trials.

In his address to the nation on December 25, Prime Minister Narendra Modi had assured that soon the country will develop a nasal vaccine.

More News

Bhagwant Mann Challenges CM Channi To Fight Against Him From Dhuri, Punjab

Bhagwant Mann has challenged Punjab Chief Minister and Congress leader Charanjit Singh Channi to fight against him from the Dhuri seat in the upcoming...

BJP Accuses Congress of Spreading Hatred In Punjab

Union Minister and Punjab BJP election in-charge Gajendra Singh Shekhawat has demanded action from the Election Commission, accusing the Congress of creating an atmosphere...

896 Indians Amongst 1,214 Players Registered For IPL 2022 Auction

After the registration for the Indian Premier League (IPL) 2022 player auction ended on January 20, the tournament said in an official advisory that...


Sensex Slips 600 points, Nifty Ends Below 17,800

Benchmark indices ended lower on January 20 on the back of continues profit booking, with Nifty closing below 17800. At close, the Sensex was down...

Microsoft-Activision Blizzard Deal May Face Scrutiny By Antitrust Enforcers In US

Microsoft Corporations proposed $75 billion acquisition of Activision Blizzard Inc. is likely to receive a close look from antitrust enforcers in the US and...

Digital Payments Adoption Accelerating: RBI-Digital Payments Index

There has been a significant growth in adoption as well as deepening of digital payments across the country, showed the Reserve Bank of India...